CN104623569A - Traditional Chinese medicine composition for treating peptic ulcer of stomach and application of traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition for treating peptic ulcer of stomach and application of traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN104623569A CN104623569A CN201510113062.8A CN201510113062A CN104623569A CN 104623569 A CN104623569 A CN 104623569A CN 201510113062 A CN201510113062 A CN 201510113062A CN 104623569 A CN104623569 A CN 104623569A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- traditional chinese
- ulcer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the field of medicines, and relates to a traditional Chinese medicine composition for treating peptic ulcer of the stomach and an application of the traditional Chinese medicine composition. Aiming at overcoming the defects of the prior art and relieving the pain of patients with peptic ulcer of the stomach, the invention provides the traditional Chinese medicine composition for treating peptic ulcer of the stomach, which is prepared from the following raw materials in parts by weight: 10-12 parts of immature bitter orange, 5-8 parts of bletilla striata, 6-9 parts of lily, 3-5 parts of oyster, 10-12 parts of pericarpium citri reticulatae, 10-12 parts of hedyotis diffusa, 3-5 parts of lotus seed, 3-5 parts of turmeric, 10-12 parts of codonopsis pilosula, 8-10 parts of mint, 6-9 parts of white peony root, 10-12 parts of rhizoma cyperi, 10-12 parts of perilla leaves, 10-12 parts of bulbus fritillariae cirrhosae, 12-15 parts of lysimachia christinae hance and 9-12 parts of liquorice. The treatment medicine has significant anti-inflammatory analgesic activity, is significant in curative effect, safe and reliable, and has a wide clinical application prospect.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of Chinese medicine composition for the treatment of round ulcer and uses thereof.
Background technology
Gastric ulcer (Gastric ulcer, GU) is a kind of commonly encountered diseases, frequently-occurring disease, and complication is many, and healing is comparatively slow, and its pathogenesis still imperfectly understands at present, and direct harm humans is healthy, there is no specificity radical cure measure so far.Any one can cause invasion and attack factor to be strengthened or the effect of protectiveness factor reduction all can cause ulcer, and its complication has upper gastrointestinal hemorrhage, perforated ulcer, pyloric obstruction, canceration etc.The whole world about has the people of 1/10 to suffer from Symptomatic peptic ulcer in life, if consider asymptomatic ulcer simultaneously, real peptic ulcer prevalence may up to 1/5, the U.S. annual new cases 500,000 people, recurrent cases about 4,000,000 people, over-65s old people accounts for 16% because of peptic ulcer hospitalization or died.The U.S. has 15 every year, dies from the complication of Peptic Ulcers about 000 people, and the medical expense relevant to Peptic Ulcers is then more than 15,000,000,000 U.S. dollars.China suffers from the chronic peptic ulcer state of an illness at present every year and reports and reach 2,000 ten thousand people, have wrong treatment to prolong and control, be converted into gastric cancer, death reaches more than 200 ten thousand people, serious harm people's health.
The medicine of current treatment gastric ulcer has a lot, mainly can be divided into following several: (1) acid inhibitor: hydrotalcite, aluminium hydroxide, magnesium oxide, calcium carbonate etc.; (2) bisfentidine: cimetidine, ranitidine, famotidine etc.; (3) proton pump inhibitor: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole etc.; (4) pyloric spirobacterium inhibitor: metronidazole, clarithromycin, amoxicillin etc.; (5) gastric mucosa protective agent: Colloidal Bismuth Tartrate capsule, bismuth citrate clock, sucralfate, teprenone etc.; (6) compound Chinese medicinal preparation: Kangfuxin Liquid, Jianweiyuyang Tablets, Weikang capsule for curing gastric disease, cyperus-amomum stomach sheet etc.; (7) medicine for stomach dynamic: JUYUANSUNMOSHABILI capsule, domperidone tablet, Metoclopramide Tablets, cisapride etc.
Along with increasing of medicament categories, clinical treat gastric ulcer time many drug combinations, conventional drug combination prescription is as follows: (1) omeprazole enteric-coated capsules+domperidone tablet+Kangfuxin Liquid; (2) Ranitidine Capsules+metronidazole; (3) omeprazole enteric-coated capsules+sucralfate; (4) lansoprazole+bangxiaoan; (5) omeprazole+levofloxacin+clarithromycin; (6) omeprazole+amoxicillin+metronidazole; (7) lansoprazole+JUYUANSUNMOSHABILI capsule+Colloidal Bismuth Tartrate capsule.
Most of chemotherapeutic agent, for enhancing gastric motility, solves stomachache, gastric acid, flatulence and repairs the several cardinal symptom of gastric mucosa and carry out strengthening demand.But treatment and the recovery of gastropathy are absolutely not that solution table disease demand just can complete.Domestic compound Chinese medicinal preparation has also played irreplaceable effect in the treatment of gastric ulcer, especially improving in symptom, clinical conventional compound Chinese medicinal preparation has Jianweiyuyang Tablets and Kangfuxin Liquid all to achieve good clinical therapeutic efficacy, but these medicine onsets are slow, and therapeutic effect often varies with each individual, therapeutic effect is imprecise, is therefore still necessary to further investigate the Chinese traditional treatment medicine for the treatment of round ulcer disease.It is rapid that the present invention aims to provide onset, Chinese medicine composition that therapeutic effect is definite and uses thereof.
Summary of the invention
In order to make up the deficiencies in the prior art, alleviate the misery of round ulcer patient, the invention provides a kind of Chinese medicine composition for the treatment of round ulcer, its clinical efficacy is remarkable, toxic and side effects is low, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
Treat a Chinese medicine composition for round ulcer, this Chinese medicine composition is made up of the raw material of following weight portion: Fructus Aurantii Immaturus 10-12 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 5-8 part, Bulbus Lilii 6-9 part, Concha Ostreae 3-5 part, Pericarpium Citri Reticulatae 10-12 part, Herba Hedyotidis Diffusae 10-12 part, Semen Nelumbinis 3-5 part, Rhizoma Curcumae Longae 3-5 part, Radix Codonopsis 10-12 part, Herba Menthae 8-10 part, Radix Paeoniae Alba 6-9 part, Rhizoma Cyperi 10-12 part, Folium Perillae 10-12 part, Bulbus Fritillariae Cirrhosae 10-12 part, Herba Lysimachiae 12-15 part, Radix Glycyrrhizae 9-12 part.
In Chinese medicine composition described above, various Chinese medicinal components is all got its conventional agents area and is used as medicine.According to its therapeutic effect to round ulcer, described Chinese medicine composition is made up of the raw material of following weight portion: Fructus Aurantii Immaturus 11 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 7 parts, Bulbus Lilii 7 parts, Concha Ostreae 4 parts, Pericarpium Citri Reticulatae 11 parts, Herba Hedyotidis Diffusae 11 parts, 4 parts, Semen Nelumbinis, 4 parts, Rhizoma Curcumae Longae, Radix Codonopsis 11 parts, Herba Menthae 9 parts, the Radix Paeoniae Alba 8 parts, Rhizoma Cyperi 11 parts, Folium Perillae 11 parts, Bulbus Fritillariae Cirrhosae 11 parts, Herba Lysimachiae 13 parts, 10 parts, Radix Glycyrrhizae.
In Chinese medicine composition described above, Radix Polygalae 5-8 part magnolia obovata 12-15 part can also be contained.These two kinds of Chinese medicines can strengthen the anti-inflammatory pain-stopping effect of the above-mentioned Chinese medicine composition of the present invention further.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment round ulcer medicine.Pharmaceutical composition of the present invention, when treating round ulcer, demonstrates remarkable anti-inflammatory and antalgic activity.Test examples 7 of the present invention shows, positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of each dosage group of Chinese medicine composition of the present invention and positive controls have pole significance difference XOR significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.Test examples 8 mice of the present invention licks foot response latency time showing, after administration after 1h and 2h the mice of each administration group of Chinese medicine composition of the present invention add foot reaction incubation period be all greater than model group, there is dose-dependence, and be significantly greater than model group (P < 0.05) incubation period of high dose group.What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has significant analgesic activity.Under same experiment condition, the analgesic effect of positive control drug hydrocortisone group is not as good as Chinese medicine composition of the present invention.The embodiment of the present invention 9 Chinese medicine composition of the present invention shows the therapeutic effect of round ulcer, and Drug therapy round ulcer of the present invention has good effect, has higher cure rate and effective percentage compared with existing medicine.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Chinese medicine composition of the present invention, in treatment round ulcer, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and improves the quality of life of patient.
2) multi-medicament component is contained in Chinese medicine composition of the present invention, action target spot is numerous, pharmacological evaluation shows it and existing medicine has significant synergism in anti-inflammatory and antalgic, and significantly can reduce round ulcer patient and occur pain symptom, improve acceptance and the compliance of patient.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
(1) example of formulations part
Embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Aurantii Immaturus 10 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 5 parts, Bulbus Lilii 6 parts, Concha Ostreae 3 parts, Pericarpium Citri Reticulatae 10 parts, Herba Hedyotidis Diffusae 10 parts, 3 parts, Semen Nelumbinis, 3 parts, Rhizoma Curcumae Longae, Radix Codonopsis 10 parts, Herba Menthae 8 parts, the Radix Paeoniae Alba 6 parts, Rhizoma Cyperi 10 parts, Folium Perillae 10 parts, Bulbus Fritillariae Cirrhosae 10 parts, Herba Lysimachiae 12 parts, 9 parts, Radix Glycyrrhizae.
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Aurantii Immaturus 12 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 8 parts, Bulbus Lilii 9 parts, Concha Ostreae 5 parts, Pericarpium Citri Reticulatae 12 parts, Herba Hedyotidis Diffusae 12 parts, 5 parts, Semen Nelumbinis, 5 parts, Rhizoma Curcumae Longae, Radix Codonopsis 12 parts, Herba Menthae 10 parts, the Radix Paeoniae Alba 9 parts, Rhizoma Cyperi 12 parts, Folium Perillae 12 parts, Bulbus Fritillariae Cirrhosae 12 parts, Herba Lysimachiae 15 parts, 12 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 3 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Aurantii Immaturus 11 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 7 parts, Bulbus Lilii 7 parts, Concha Ostreae 4 parts, Pericarpium Citri Reticulatae 11 parts, Herba Hedyotidis Diffusae 11 parts, 4 parts, Semen Nelumbinis, 4 parts, Rhizoma Curcumae Longae, Radix Codonopsis 11 parts, Herba Menthae 9 parts, the Radix Paeoniae Alba 8 parts, Rhizoma Cyperi 11 parts, Folium Perillae 11 parts, Bulbus Fritillariae Cirrhosae 11 parts, Herba Lysimachiae 13 parts, 10 parts, Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Aurantii Immaturus 10 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 5 parts, Bulbus Lilii 6 parts, Concha Ostreae 3 parts, Pericarpium Citri Reticulatae 10 parts, Herba Hedyotidis Diffusae 10 parts, 3 parts, Semen Nelumbinis, 3 parts, Rhizoma Curcumae Longae, Radix Codonopsis 10 parts, Herba Menthae 8 parts, the Radix Paeoniae Alba 6 parts, Rhizoma Cyperi 10 parts, Folium Perillae 10 parts, Bulbus Fritillariae Cirrhosae 10 parts, Herba Lysimachiae 12 parts, 9 parts, Radix Glycyrrhizae, Radix Polygalae 5 parts, Cortex Magnoliae Officinalis 13 parts
Preparation method is with embodiment 1.
Embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Aurantii Immaturus 12 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 8 parts, Bulbus Lilii 9 parts, Concha Ostreae 5 parts, Pericarpium Citri Reticulatae 12 parts, Herba Hedyotidis Diffusae 12 parts, 5 parts, Semen Nelumbinis, 5 parts, Rhizoma Curcumae Longae, Radix Codonopsis 12 parts, Herba Menthae 10 parts, the Radix Paeoniae Alba 9 parts, Rhizoma Cyperi 12 parts, Folium Perillae 12 parts, Bulbus Fritillariae Cirrhosae 12 parts, Herba Lysimachiae 15 parts, 12 parts, Radix Glycyrrhizae, Radix Polygalae 8 parts, Cortex Magnoliae Officinalis 12 parts.
Preparation method is with embodiment 1.
Embodiment 6 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Aurantii Immaturus 11 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 7 parts, Bulbus Lilii 7 parts, Concha Ostreae 4 parts, Pericarpium Citri Reticulatae 11 parts, Herba Hedyotidis Diffusae 11 parts, 4 parts, Semen Nelumbinis, 4 parts, Rhizoma Curcumae Longae, Radix Codonopsis 11 parts, Herba Menthae 9 parts, the Radix Paeoniae Alba 8 parts, Rhizoma Cyperi 11 parts, Folium Perillae 11, Bulbus Fritillariae Cirrhosae 11 parts, Herba Lysimachiae 13 parts, 10 parts, Radix Glycyrrhizae, Radix Polygalae 6 parts, Cortex Magnoliae Officinalis 15 parts.
Preparation method is with embodiment 1.
(2) test examples part
The antiinflammatory action of embodiment 7 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone has stronger anti-inflammatory activity, be synthetic be also naturally occurring glucocorticoid, after hydrocortisone enters cell, activate cytoplasmic receptor, nucleus is entered after allosteric, be combined with DNA response element, cause suppression or the induction of genetic transcription, the expression of inflammation related proteins is changed.
1, experimental technique:
40 KM mices, male and female half and half, body weight 25-30 gram, five groups are divided at random, i.e. dosage group in model control group, combination group high dose group, compositions, compositions low dose group, positive controls by body weight, often organize 10, each administration group mice gives following medicine respectively:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 5g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in compositions: gavage gives 2g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Compositions low dose group: gavage gives 0.5g/kg embodiment 1 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Each administration group is administered once every day, successive administration 7d.Get dimethylbenzene 20 μ l after last administration, be applied to each mouse right ear.Get after 30 minutes and be respectively evenly applied to mouse right ear respectively by reagent 0.03ml, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
2, experimental result:
Measure the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is in table 1.
Table 1 each experimental mice ear method of double differences compares
| Group | n | The ear method of double differences (mg) |
| Model control group | 10 | 8.94±1.26 |
| Positive controls | 10 | 6.15±1.31 * |
| Compositions high dose group | 10 | 3.49±1.75 **## |
| Dosage group in compositions | 10 | 4.68±1.38 **# |
| Compositions low dose group | 10 | 6.04±1.33 * |
Compare with model control group,
*p < 0.05; Compare with model control group,
*p < 0.01;
Compare with positive controls,
#p < 0.05; Compare with positive controls,
##p < 0.01.
Result display gives positive drug and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have pole significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group significantly will be better than positive controls.
Embodiment 8 Chinese medicine composition of the present invention affects mouse hot-plate analgesic
1 mouse hot-plate pain model makes
About body weight 20g female mice is placed on hot plate dolorimeter, screen qualified ♀ mice 90 (to lick metapedes time <5s or >30s to throw aside, scald for preventing foot, also deadline should be established, be generally 60s), the incubation period of metapedes reaction is added for threshold of pain index with mice, get 72 jennies, be divided into 56 groups, 12/group, i.e. model group, hydrocortisone group, Chinese medicine composition of the present invention (obtaining by Chinese medicine composition prescription described in embodiment 1 and preparation technology) low dose group, middle dosage group and high dose group.Each group is gastric infusion, 1 times/day, and dosage is with the embodiment of the present invention 7, and after successive administration 7d, after measuring last medicine, 60min, 120min add the time of foot reaction.
2 Chinese medicine compositions of the present invention are on the impact of licking the foot response latency in mouse hot-plate analgesic experiment
Mice licks foot response latency time showing, compare with model group, after administration after 1h and 2h, the incubation period that the mice of each administration group of Chinese medicine composition of the present invention adds foot reaction is all greater than model group, there is dose-dependence, and be significantly greater than model group (P < 0.05) incubation period of high dose group.What illustrate that this Chinese medicine composition of the present invention can extend that mice stimulates hot plate adds the sufficient response latency, has certain analgesic activity.Under same experiment condition, positive control drug cydiodine group (P < 0.05) and Huanglianshangqing Tablet group (1h, P < 0.05; 2h, P < 0.01) also extend the incubation period that mice adds foot reaction, there is certain analgesic activity, but its analgesic effect and model group there was no significant difference.The results are shown in Table 2.
Table 2 mice licks foot response latency timetable
| Group | Dosage (mg/kg) | 1h(s) | 2h(s) |
| Model group | - | 22.8±3.6 | 22.5±6.3 |
| Hydrocortisone | 150 | 23.8±2.9 | 24.1±2.4 |
| Compositions low dose group | 500 | 26.5±1.9* | 27.1±1.8* # |
| Dosage group in compositions | 2000 | 27.6±2.1* # | 28.4±2.4* # |
| Compositions high dose group | 5000 | 29.5±2.4** ## | 29.5±1.8** ## |
Note: compare with model group, * P < 0.05, * * P < 0.01; Compare with hydrocortisone group,
#p < 0.05,
##p < 0.01
Embodiment 9 Chinese medicine composition of the present invention is to the therapeutic effect of acetic acid rat gastric ulcer model round ulcer
The foundation of acetic acid rat gastric ulcer model: inject 10% chloral hydrate 1ml after SD Rat Fast (can't help water) 24h and anaesthetize, lie on the back and be fixed on operating-table, alcohol disinfecting abdominal part, xiphoid-process median incision of lower abdomen about 1.5cm, after opening abdomen, stomach is pulled out, at the facies ventralis of stomach, body of stomach and pyloric part intersection, 0.5 ~ 0.6mm under serous coat is thrust by flat for microsyringe, inject 20% acetic acid 0.05ml and form pimple, stomach is sent back to abdominal cavity with after normal saline flushing, suturing them, sterilization wound, the Rat Fast on the same day (can't help water) of operation, start conventional raising next day, within 3rd, observe modeling situation afterwards, observe and find to form typical circle or oval volcanic crater sample gastric ulcer in rat stomach, swell because of congestion and edema around ulcer, intermediate recess, and ulcer surrounding mucosa pleat is thicker, part is in the asterism shape centered by ulcer, ulcer can reach muscle layer deeply, with one deck ash white fur on it.
The acetic acid rat gastric ulcer model of foundation is divided into five groups in 3 days afterwards at random: each group administrations is as shown in table 3, and Chinese medicine composition of the present invention obtains by Chinese medicine composition prescription described in embodiment 1 and preparation technology.Successive administration 14 days is respectively at administration 0d, 5d, 14d stochastic sampling is dissected rat and is observed ulcer situation, calculate ulcer area, the computational methods of the area of ulcer: cervical dislocation puts to death rat, open abdominal cavity, stomach is pulled out, cut along greater gastric curvature after taking out stomach, with 37 DEG C of normal saline, gastric mucosa is rinsed well, blot with filter paper, flatten, be placed on ice platform, with major diameter (DL) and the minor axis (DS) of vernier caliper measurement ulcer, calculate the area of ulcer, calculate by formula S=DL × DS × π/4, π gets 3.14;
After administration 5d, model control group ulcer is still very serious, surface is covered with white fur, average ulcer area reaches after 82.5mm2 treats 14 days, model control group is all dead, the medication group mental status is fine, freedom of movement, observes after dissecting, medication group 1 naked eyes do not observe ulcer completely, and each group ulcer area is more as shown in table 3.
Table 3 respectively group ulcer area compares (mm2)
| Group | Dosage (mg/kg) | Administration 0d | Administration 5d | Administration 14d |
| Model group | - | 83.9±3.6 | 82.5±6.3 | 80.9±1.2 |
| Hydrocortisone | 150 | 83.8±2.9 | 64.1±2.4 | 16.1±1.3 * |
| Compositions low dose group | 500 | 84.5±1.9* | 27.1±1.8* # | 7.4±1.7 **## |
| Dosage group in compositions | 2000 | 84.6±2.1* # | 25.4±2.4* # | 5.6±1.3 **## |
| Compositions high dose group | 5000 | 84.5±2.4** ## | 21.5±1.8** ## | 3.0±1.3** ## |
Note: compare with model group, * P < 0.05, * * P < 0.01; Compare with hydrocortisone group,
#p < 0.05,
##p < 0.01.
Claims (7)
1. treat the Chinese medicine composition of round ulcer for one kind, it is characterized in that, it is made up of the raw material of following weight portion: Fructus Aurantii Immaturus 10-12 part, Pseudobulbus Bletillae (Rhizoma Bletillae) 5-8 part, Bulbus Lilii 6-9 part, Concha Ostreae 3-5 part, Pericarpium Citri Reticulatae 10-12 part, Herba Hedyotidis Diffusae 10-12 part, Semen Nelumbinis 3-5 part, Rhizoma Curcumae Longae 3-5 part, Radix Codonopsis 10-12 part, Herba Menthae 8-10 part, Radix Paeoniae Alba 6-9 part, Rhizoma Cyperi 10-12 part, Folium Perillae 10-12 part, Bulbus Fritillariae Cirrhosae 10-12 part, Herba Lysimachiae 12-15 part, Radix Glycyrrhizae 9-12 part.
2. Chinese medicine composition as claimed in claim 1, is characterized in that, described Chinese medicine composition is also containing Radix Polygalae 5-8 part magnolia obovata 12-15 part.
3. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition is made up of the raw material of following weight portion: Fructus Aurantii Immaturus 11 parts, the Pseudobulbus Bletillae (Rhizoma Bletillae) 7 parts, Bulbus Lilii 7 parts, Concha Ostreae 4 parts, Pericarpium Citri Reticulatae 11 parts, Herba Hedyotidis Diffusae 11 parts, 4 parts, Semen Nelumbinis, 4 parts, Rhizoma Curcumae Longae, Radix Codonopsis 11 parts, Herba Menthae 9 parts, the Radix Paeoniae Alba 8 parts, Rhizoma Cyperi 11 parts, Folium Perillae 11 parts, Bulbus Fritillariae Cirrhosae 11 parts, Herba Lysimachiae 13 parts, 10 parts, Radix Glycyrrhizae.
4. Chinese medicine composition as claimed in claim 4, is characterized in that, described Chinese medicine composition is also containing Radix Polygalae 5-8 part magnolia obovata 12-15 part.
5. Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that, described Chinese medicine composition is powder, water preparation, tablet or capsule.
6. Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that, the preparation method of described Chinese medicine composition comprises following step: get recipe quantity Chinese crude drug and be broken into coarse powder, adds according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filter, filtrate recycling ethanol, cold filtration, wash with water, after drying, namely obtain Chinese medical concrete; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
7. the purposes of the Chinese medicine composition described in claim 1 or 2 in preparation treatment round ulcer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510113062.8A CN104623569A (en) | 2015-03-13 | 2015-03-13 | Traditional Chinese medicine composition for treating peptic ulcer of stomach and application of traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510113062.8A CN104623569A (en) | 2015-03-13 | 2015-03-13 | Traditional Chinese medicine composition for treating peptic ulcer of stomach and application of traditional Chinese medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104623569A true CN104623569A (en) | 2015-05-20 |
Family
ID=53203131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510113062.8A Pending CN104623569A (en) | 2015-03-13 | 2015-03-13 | Traditional Chinese medicine composition for treating peptic ulcer of stomach and application of traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104623569A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105169280A (en) * | 2015-10-13 | 2015-12-23 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating duodenal ulcer complicated with ulcerative colitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406599A (en) * | 2008-12-05 | 2009-04-15 | 正大青春宝药业有限公司 | Pharmaceutical composition for treating chronic atrophic gastritis |
| JP2010184914A (en) * | 2009-02-13 | 2010-08-26 | Bizen Chemical Co Ltd | Composition having proton pump inhibitory activity |
| CN102631555A (en) * | 2012-05-09 | 2012-08-15 | 刘宗奎 | Novel gastrointestinal mucosa injury repair medicament and preparation method thereof |
-
2015
- 2015-03-13 CN CN201510113062.8A patent/CN104623569A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406599A (en) * | 2008-12-05 | 2009-04-15 | 正大青春宝药业有限公司 | Pharmaceutical composition for treating chronic atrophic gastritis |
| JP2010184914A (en) * | 2009-02-13 | 2010-08-26 | Bizen Chemical Co Ltd | Composition having proton pump inhibitory activity |
| CN102631555A (en) * | 2012-05-09 | 2012-08-15 | 刘宗奎 | Novel gastrointestinal mucosa injury repair medicament and preparation method thereof |
Non-Patent Citations (7)
| Title |
|---|
| 《新赤脚医生手册》编辑部: "《新赤脚医生手册》", 30 April 2007, 陕西师范大学出版社 * |
| 任平均等: "变通香苏散治疗慢性胃炎消化性溃疡185例", 《河北中医》 * |
| 周德生等: "《中医验方全书【珍藏本】超值版》", 31 August 2013, 湖南科学技术出版社 * |
| 尹国有等: "《消化性溃疡用药与食疗》", 31 May 2012, 金盾出版社 * |
| 徐元贞等: "《中华方药宝典》", 31 March 2012, 河南科学技术出版社 * |
| 范正祥: "《家庭百病自我治疗与护理大全》", 31 July 1991, 科学出版社 * |
| 黄碧艳: "4-7中西医结合治疗消化性溃疡的临床效果观察", 《中国医药指南》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105169280A (en) * | 2015-10-13 | 2015-12-23 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating duodenal ulcer complicated with ulcerative colitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830686B (en) | A kind of Chinese medicine composition for the treatment of hemorrhoid and uses thereof | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103341063B (en) | Chinese medicine composition for treating wind-heat cough | |
| CN103356932B (en) | A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN104623569A (en) | Traditional Chinese medicine composition for treating peptic ulcer of stomach and application of traditional Chinese medicine composition | |
| CN103977370A (en) | Pharmaceutical composition with effect of inducing diuresis to alleviate edema | |
| CN103585545B (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN104547683B (en) | A kind of Chinese medicine composition for treating chronic gastritis and preparation method thereof | |
| CN104825691A (en) | Traditional Chinese medicine composition for treating duodenal ulcer and application of traditional Chinese medicine composition | |
| CN102357217B (en) | Chinese patent medicine for treating gastric ulcer | |
| CN103520367A (en) | Pharmaceutical composition for treating urticaria, and preparation method and application thereof | |
| CN104435629B (en) | A kind of recurrent oral ulceration for the treatment of merges Chinese medicine of laryngopharynx swelling and pain and uses thereof | |
| CN104587137A (en) | Traditional Chinese medicine composition for treating aseptic cervicoshoulder myofascitis and preparation method thereof | |
| CN101264302A (en) | Application of Chinese medicinal composition in preparing medicaments for treating menoxenia and menorrhalgia | |
| CN104435133A (en) | Medicament for reducing fever | |
| CN105169280A (en) | Traditional Chinese medicine composition for treating duodenal ulcer complicated with ulcerative colitis | |
| CN104623256A (en) | Traditional Chinese medicine composition for treating nasosinusitis | |
| CN104825808A (en) | Chinese medicinal composition for treating chronic pharyngitis and preparation method thereof | |
| CN104998154A (en) | Traditional Chinese medicine compound treating cervical spondylosis and acute pharyngitis | |
| CN104324212A (en) | Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof | |
| CN103316258B (en) | Medicine composition for treating infantile vaginitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150520 |
|
| WD01 | Invention patent application deemed withdrawn after publication |